Drugs & Targets FDA Approves New Indications for Darzalex, Keytruda, Opdivo November 29, 2016Vol.39 No.10
Phase III Keytruda Study Shows Better OS vs. Chemo for Advanced Urothelial Cancer November 29, 2016Vol.39 No.10
Binimetinib plus encorafenib produces PFS improvement vs vemurafenib monotherapy November 29, 2016Vol.39 No.10
Free MD Anderson Sues Billionaire Over Using the Word “Moonshot” November 18, 2016Vol.42 No.43By Paul Goldberg
Free Republicans Ditch 2017 Appropriations To Tailor Spending to Trump Priorities November 18, 2016Vol.42 No.43By Matthew Bin Han Ong
Conversation with The Cancer Letter FDA Eager to Approve PD-1 and PD-L1 Drugs in Novel Combinations, New Settings November 11, 2016Vol.42 No.42By Paul Goldberg
Fred Hutchinson Opens Cellular Immunotherapy Clinic November 11, 2016Vol.42 No.42By Matthew Bin Han Ong
Free What the Trump Presidency Means for Cancer Care, the ACA, and the Moonshot November 10, 2016Vol.42 No.42By Matthew Bin Han Ong
Free Cancer Moonshot Research Dollars Must Go to NCI—Not NIH—Groups Say November 04, 2016Vol.42 No.41By Matthew Bin Han Ong
FreeGuest Editorial A Countdown: Top 10 Problems With NCI-Designated Cancer Centers November 04, 2016Vol.42 No.41By David Rubenson
